Drotrecogin alfa activated (Xigris)
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End Stage Renal Disease
Conditions
End Stage Renal Disease
Trial Timeline
Oct 1, 2008 → Dec 1, 2010
NCT ID
NCT01227187About Drotrecogin alfa activated (Xigris)
Drotrecogin alfa activated (Xigris) is a phase 2 stage product being developed by Eli Lilly for End Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01227187. Target conditions include End Stage Renal Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01227187 | Phase 2 | Completed |
Competing Products
20 competing products in End Stage Renal Disease